On Metformin: Oral intake of Metformin (1 g / day) for 2 weeks
Off Metformin: No oral intake of Metformin (1 g / day) for 2 weeks
Study summary
Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion criteria:
* type 2 diabetes (duration \<7 years),
* age (18-75 years)
* BMI \<40 kg/m2
* HbA1c 6-15%
Exclusion criteria:
* uncontrolled hyperglycaemia (\>340 mg/dl)
* diabetes types other than type 2 diabetes (ADA criteria)
* thiazolidinedione use during the preceding 6 months
* clinically relevant angiopathy, restrictive or obstructive lung diseases
* other acute or chronic diseases including wounds and the use of pharmacological agents known to affect insulin sensitivity, lipid metabolism or immunological function.
Primary outcome measure(s)
Hepatic gluconeogenic flux (U-13C-lactate tracer) (mg/min) — 2 weeks Hepatic gluconeogenic flux rates from lactate \[mg/min\] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.
Hepatic gluconeogenic flux (glycerol tracer) (mg/min) — 2 weeks Hepatic gluconeogenic flux rates from glycerol \[mg/min\] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.